Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

D. H. Henry, B. J. Brooks, D. C. Case, E. Fishkin, R. Jacobson, A. M. Keller, J. Kugler, J. Moore, R. T. Silver, Anna Maria Storniolo, R. I. Abels, D. S. Gordon, R. Nelson, K. Larholt, E. Bryant, S. Rudnick

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

PURPOSE: To assess whether the administration of recombinant human erythropoietin (r-HuEPO) would increase the hematocrit, reduce the requirement for transfusion, and improve the quality of life in anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. PATIENTS AND METHODS: One hundred thirty-two anemic cancer patients receiving cyclic, cisplatin-containing, myelosuppressive chemotherapy were evaluated. Patients received either r-HuEPO (150 U/kg) or placebo, subcutaneously, three times a week for 3 months. Responses were assessed by measuring changes in hemoglobin/hematocrit, transfusion requirement, and quality of life. RESULTS: The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group. A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement. Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively). However, the magnitude of this difference was not helpful in defining which patients were likely to respond. There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group. There were no significant adverse effects associated with r-HuEPO. CONCLUSIONS: r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.

Original languageEnglish (US)
Pages (from-to)252-260
Number of pages9
JournalCancer Journal from Scientific American
Volume1
Issue number4
StatePublished - Nov 1995
Externally publishedYes

Fingerprint

Erythropoietin
Cisplatin
Drug Therapy
Neoplasms
Hematocrit
Placebos
Quality of Life
Therapeutics
Hemoglobins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Henry, D. H., Brooks, B. J., Case, D. C., Fishkin, E., Jacobson, R., Keller, A. M., ... Rudnick, S. (1995). Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer Journal from Scientific American, 1(4), 252-260.

Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. / Henry, D. H.; Brooks, B. J.; Case, D. C.; Fishkin, E.; Jacobson, R.; Keller, A. M.; Kugler, J.; Moore, J.; Silver, R. T.; Storniolo, Anna Maria; Abels, R. I.; Gordon, D. S.; Nelson, R.; Larholt, K.; Bryant, E.; Rudnick, S.

In: Cancer Journal from Scientific American, Vol. 1, No. 4, 11.1995, p. 252-260.

Research output: Contribution to journalArticle

Henry, DH, Brooks, BJ, Case, DC, Fishkin, E, Jacobson, R, Keller, AM, Kugler, J, Moore, J, Silver, RT, Storniolo, AM, Abels, RI, Gordon, DS, Nelson, R, Larholt, K, Bryant, E & Rudnick, S 1995, 'Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.', Cancer Journal from Scientific American, vol. 1, no. 4, pp. 252-260.
Henry DH, Brooks BJ, Case DC, Fishkin E, Jacobson R, Keller AM et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer Journal from Scientific American. 1995 Nov;1(4):252-260.
Henry, D. H. ; Brooks, B. J. ; Case, D. C. ; Fishkin, E. ; Jacobson, R. ; Keller, A. M. ; Kugler, J. ; Moore, J. ; Silver, R. T. ; Storniolo, Anna Maria ; Abels, R. I. ; Gordon, D. S. ; Nelson, R. ; Larholt, K. ; Bryant, E. ; Rudnick, S. / Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. In: Cancer Journal from Scientific American. 1995 ; Vol. 1, No. 4. pp. 252-260.
@article{794dd0bceab1400ba8f027d42e397921,
title = "Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.",
abstract = "PURPOSE: To assess whether the administration of recombinant human erythropoietin (r-HuEPO) would increase the hematocrit, reduce the requirement for transfusion, and improve the quality of life in anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. PATIENTS AND METHODS: One hundred thirty-two anemic cancer patients receiving cyclic, cisplatin-containing, myelosuppressive chemotherapy were evaluated. Patients received either r-HuEPO (150 U/kg) or placebo, subcutaneously, three times a week for 3 months. Responses were assessed by measuring changes in hemoglobin/hematocrit, transfusion requirement, and quality of life. RESULTS: The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group. A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27{\%} r-HuEPO vs. 56{\%} placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement. Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively). However, the magnitude of this difference was not helpful in defining which patients were likely to respond. There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group. There were no significant adverse effects associated with r-HuEPO. CONCLUSIONS: r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.",
author = "Henry, {D. H.} and Brooks, {B. J.} and Case, {D. C.} and E. Fishkin and R. Jacobson and Keller, {A. M.} and J. Kugler and J. Moore and Silver, {R. T.} and Storniolo, {Anna Maria} and Abels, {R. I.} and Gordon, {D. S.} and R. Nelson and K. Larholt and E. Bryant and S. Rudnick",
year = "1995",
month = "11",
language = "English (US)",
volume = "1",
pages = "252--260",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

AU - Henry, D. H.

AU - Brooks, B. J.

AU - Case, D. C.

AU - Fishkin, E.

AU - Jacobson, R.

AU - Keller, A. M.

AU - Kugler, J.

AU - Moore, J.

AU - Silver, R. T.

AU - Storniolo, Anna Maria

AU - Abels, R. I.

AU - Gordon, D. S.

AU - Nelson, R.

AU - Larholt, K.

AU - Bryant, E.

AU - Rudnick, S.

PY - 1995/11

Y1 - 1995/11

N2 - PURPOSE: To assess whether the administration of recombinant human erythropoietin (r-HuEPO) would increase the hematocrit, reduce the requirement for transfusion, and improve the quality of life in anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. PATIENTS AND METHODS: One hundred thirty-two anemic cancer patients receiving cyclic, cisplatin-containing, myelosuppressive chemotherapy were evaluated. Patients received either r-HuEPO (150 U/kg) or placebo, subcutaneously, three times a week for 3 months. Responses were assessed by measuring changes in hemoglobin/hematocrit, transfusion requirement, and quality of life. RESULTS: The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group. A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement. Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively). However, the magnitude of this difference was not helpful in defining which patients were likely to respond. There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group. There were no significant adverse effects associated with r-HuEPO. CONCLUSIONS: r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.

AB - PURPOSE: To assess whether the administration of recombinant human erythropoietin (r-HuEPO) would increase the hematocrit, reduce the requirement for transfusion, and improve the quality of life in anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. PATIENTS AND METHODS: One hundred thirty-two anemic cancer patients receiving cyclic, cisplatin-containing, myelosuppressive chemotherapy were evaluated. Patients received either r-HuEPO (150 U/kg) or placebo, subcutaneously, three times a week for 3 months. Responses were assessed by measuring changes in hemoglobin/hematocrit, transfusion requirement, and quality of life. RESULTS: The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group. A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement. Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively). However, the magnitude of this difference was not helpful in defining which patients were likely to respond. There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group. There were no significant adverse effects associated with r-HuEPO. CONCLUSIONS: r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy. After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.

UR - http://www.scopus.com/inward/record.url?scp=0002929285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002929285&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 252

EP - 260

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 4

ER -